Orbcel-C is under clinical development by Orbsen Therapeutics and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase II drugs for Lupus Nephritis have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Orbcel-C’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Stem cell therapy is under development for the treatment of primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), rheumatoid Arthritis, lupus Nephritis, crohn''s Disease and acute respiratory distress syndrome (ARDS) caused by COVID-19. The therapeutic candidate constitutes pure and defined mesenchymal stromal cells (MSCs) isolated from adult bone marrow. It is administered through intravenous drip and intravenous infusion. It is based on ORB1 technology.
Orbsen Therapeutics overview
Orbsen Therapeutics is a regenerative medicine company focused on developing stromal cell treatments to address some of most challenging diseases. Orbsen Therapeutics is headquartered in Galway, Ireland.
For a complete picture of Orbcel-C’s drug-specific PTSR and LoA scores, buy the report here.